Ajanta Pharma Limited, a specialty focused pharmaceutical formulation company, has posted 18% increase in net profit for the second quarter of FY 2011-12. The Profit after Tax stood at Rs.11.85crores (Rs.10.05crores) for the quarter ended September 30, 2011. Net sales for the quarter stood at Rs.135.13crores (Rs.112.51crores), a growth of 20% over same period of previous year. Profit After Tax for the half year ended September 30, 2011 stood at Rs.24.38crores against Rs.17.03crores last year same period, the growth of 43%.
The Hyderabad based Dr Reddy's Laboratories has gained nearly three at Rs 1,671 after the company reported a seven percent increase in consolidated net profit at Rs 307.8 crore for the quarter ended September 30, compared to Rs 286.7 crore in the corresponding quarter last year.
The Hyderabad- based NATCO Pharma Limited has entered into an exclusive agreement with Mabxience, the bio-similar division of Chemo Sa Lugano, Switzerland, an integrated healthcare multinational involved into different fields of pharmaceutical business, including bio-similar and branded pharmaceuticals.
The potential of artificial blood sourced from stem cells to be administered to organ transplant patients are to become a reality in the next decade.
The Hyderabad-based Biosciences Private Ltd, (GVK BIO), Asia’s leading drug discovery research & development organization, has announced that the Tokyo-based Astellas Pharma Inc. has extended and renewed its license to the GVK BIO SAR Databases (GOSTAR).
The Bangalore-based, Biocon, Asia’s premier biotechnology company, has launched its reusable insulin delivery device, INSUPen. ``A world-class, differentiated device based on proprietary German technology, INSUPen® is a first-in-class reusable delivery device. It is insulin with ease. It is designed for efficiency, accuracy and safety and can deliver both Basalog™ and Insugen™, thus maximizing patient convenience’’, Biocon Chairman and MD Ms. Kiran Mazumdar-Shaw, said
Indian pharmaceutical firms will have to affix barcodes on consignments of all tertiary level packaging, such as cartons, following a government order.
Alleging that Indian pharmaceutical industry does not manufacture pure medicines, PPMA Chairman, Mian Asad Shuja Rehman said, “Though Indian medicines are cheaper, these are of low standard and their quality is not up to the mark.”
Indian drug manufacturer Lupin Pharmaceuticals Limited today said it has received final approval from the US health regulator to market a generic version of UCB's Keppra Oral Solution, an anti-epilepsy drug, in the American market.
Sun made the offer to buy the outstanding shares of Taro at $24.5 in cash, representing a 25.96 per cent premium over the most recent closing price of Taro common stock.
The Kerala-based CRAFT Hospital, a specialty infertility research and treatment centre, has launched India’s first infertility insurance scheme: ‘IVF Suraksha’. The scheme guarantees money back in case the treatment methods fail. Couple’s who yearn for a baby through in vitro fertilization (IVF) can become members of this scheme by paying Rs. 2, 50,000.
Industry Experts, a global market research organization, has released an updated version of their 2009 published market report ‘Cord Blood Stem Cells – A Global Market Overview’. The report reveals that the global market for Cord Blood Stem Cells is to touch US$7.2 billion by 2012.
The Indian pharmaceuticals and chemicals industry will be among the biggest beneficiaries of a free trade agreement between the GCC and India, a leading banker in the region has said.
The Haryana-based Eye-Q Super-specialty Eye Hospitals (Eye-Q), North India’s leading eye care chain, has announced a ‘Series B’ investment by Helion Venture Partners and Nexus Venture Partners, both India-focused VC funds. With this funding, Eye-Q is poised to expand its footprint nationally.
The Indian pharmaceutical fraternity welcomed the Government's decision to continue with 100 percent foreign direct investment in the domestic arena and further mooted a policy framework for CCI to handle pharmaceutical M&As.
